Management of Chronic Heart Failure in General Practice

Paul Smith
Consultant Cardiologist
Bradford Royal Infirmary
Presentation Overview

• Prevalence and impact
• Assessment of heart failure patient
• Aetiology and Pathophysiology
• Modern management of heart failure
• Monitoring and chronic disease management
• When to refer for Specialist advice
• Brief overview of cardiac resynchronisation therapy
The Incidence of Heart Failure

- Heart failure affects 1-2% of adult UK population
- Incidence of 5-10 cases per 1000 population per year
Heart Failure is Bad News!

One year survival rate (%)

- Pancreas
- Lung
- Oesophagus
- Stomach
- Leukaemia
- Kidney
- Ovarian
- Heart failure
- Colon
- NHL
- Prostate
- Bladder
- Uterus
- Breast
- Melanoma

British Heart Foundation, 2002
Heart Failure is Costly

- 5% of all medical admissions
- £716M per annum
- 1.8% of total NHS budget
- 70% due to hospitalisations
- Heart failure “the growing epidemic”
- Admissions predicted to rise by 50% over the next 25 years

British Heart Foundation, 2002
Chronic Heart Failure

“Heart failure is a complex syndrome that can result from any structural or functional cardiac disorder that impairs the pumping ability of the heart”
# Stages in the Development of Heart Failure

<table>
<thead>
<tr>
<th>Stage</th>
<th>Patient Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td><strong>High risk for developing heart failure (HF)</strong></td>
</tr>
<tr>
<td></td>
<td>- Coronary artery disease</td>
</tr>
<tr>
<td></td>
<td>- Hypertension</td>
</tr>
<tr>
<td></td>
<td>- Diabetes mellitus, obesity</td>
</tr>
<tr>
<td></td>
<td>- Family history of cardiomyopathy</td>
</tr>
<tr>
<td>B</td>
<td><strong>Asymptomatic HF</strong></td>
</tr>
<tr>
<td></td>
<td>- Previous myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>- Left ventricular systolic dysfunction</td>
</tr>
<tr>
<td></td>
<td>- Asymptomatic valvular disease</td>
</tr>
<tr>
<td>C</td>
<td><strong>Symptomatic HF</strong></td>
</tr>
<tr>
<td></td>
<td>- Known structural heart disease</td>
</tr>
<tr>
<td></td>
<td>- Shortness of breath and fatigue</td>
</tr>
<tr>
<td></td>
<td>- Reduced exercise tolerance</td>
</tr>
<tr>
<td>D</td>
<td><strong>Refractory end-stage HF</strong></td>
</tr>
<tr>
<td></td>
<td>- Marked symptoms at rest despite maximal medical therapy (e.g., those who are recurrently hospitalised or cannot be safely discharged from hospital without specialised interventions)</td>
</tr>
</tbody>
</table>

**Increasing severity**
Diagnosing Heart Failure

• Shortness of breath on exertion
• Fatigue (exercise intolerance)
• Orthopnoea
• Paroxysmal nocturnal dyspnoea
• Fluid retention

...symptoms are non-specific and present in many other conditions!
Masquerading as Heart Failure

- Obesity
- Venous insufficiency
- Drug induced ankle swelling
- Chest disease - pulmonary embolic disease
- Angina
- Hypoalbuminaemia
- Renal or hepatic disease
- Depression/anxiety
- Severe anaemia or thyroid disease
- Bilateral renal artery stenosis
Diagnosing Heart Failure

• The most specific signs are:
  ▪ Laterally displaced apex beat
  ▪ Elevated JVP
  ▪ Third heart sound

• Less specific signs include:
  ▪ Basal crackles
  ▪ Peripheral oedema
  ▪ Hepatic engorgement
  ▪ Tachycardia

...signs are insensitive and may not be present!
Heart Failure - baseline investigations

- FBC, U+E, LFT, TFT, glucose, lipids
- NT-pro-BNP (if available)

- Abnormal in over 90%
- LBBB, Q waves
- LVH
- AF
- ST/T wave changes
- VE, NSVT
Heart Failure Diagnostic Pathway

Suspected heart failure because of history, symptoms, and signs.

Seek to exclude heart failure through:
- 12 lead ECG
- and/or natriuretic peptides (BNP or NTproBNP) – where available.

Other recommended tests:
- chest X-ray
- blood tests: U&Es, creatinine, FBC, TFTs, LFTs, glucose, and lipids
- urinalysis, peak flow or spirometry.

Both normal
Heart failure unlikely. Consider alternative diagnosis.

One or more abnormal
Imaging by echocardiography*

No abnormality detected
Heart failure unlikely, but if diagnostic doubt persists consider diastolic dysfunction and consider referral for specialist assessment.

Abnormal
Assess HF severity, aetiology, precipitating and exacerbating factors and type of cardiac dysfunction. Correctable causes must be identified. Consider referral.

No investigation for heart failure has 100% negative predictive value. If clinical suspicion remains high then specialist referral recommended.
Echocardiography

- Single most effective tool in the diagnosis of heart failure
- Provides information on structure and function of cardiac chambers, valves and pericardium
- EF useful measure of LV systolic dysfunction
- Reports should provide information in clinical context
- Other imaging modality may need to be considered for obese and chronic lung disease
• Heart failure is **not** a complete diagnosis
• Requires more than stating whether syndrome present or not
• The following should be considered:
  - Underlying cardiac condition
  - Severity of the syndrome
  - Estimation of prognosis
  - Precipitating and exacerbating factors
  - Co-morbidity
  - Aetiology
## Impact of Comorbidities on Heart Failure Treatment

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD/Asthma</td>
<td>β Blockers are contraindicated in reversible airways disease.</td>
</tr>
<tr>
<td>Renal failure (creat&gt;200μmol/l)</td>
<td>ACEi and ARBs may be contraindicated</td>
</tr>
<tr>
<td>Thyroid</td>
<td>Severe thyroid disease may cause/precipitate HF</td>
</tr>
<tr>
<td>PVD</td>
<td>High index of suspicion of RAS</td>
</tr>
<tr>
<td>Urinary frequency</td>
<td>α blockers may cause fluid retention and hypotension. Diuretics may not be tolerated.</td>
</tr>
<tr>
<td>Gout</td>
<td>Exacerbated by diuretics. Avoid NSAID’s.</td>
</tr>
</tbody>
</table>
## NYHA Classification

<table>
<thead>
<tr>
<th>NYHA functional class</th>
<th>Definition</th>
<th>Diagnosed HF cases %</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYHA 1</td>
<td>No limitation: ordinary physical exercise does not cause dyspnoea or fatigue.</td>
<td>0</td>
</tr>
<tr>
<td>NYHA 2</td>
<td>Slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in breathlessness, fatigue, palpitations or angina (symptomatically mild heart failure).</td>
<td>69</td>
</tr>
<tr>
<td>NYHA 3</td>
<td>Marked limitation of physical activity: comfortable at rest but dyspnoea washing and dressing, or walking from room to room (symptomatically moderate heart failure).</td>
<td>15</td>
</tr>
<tr>
<td>NYHA 4</td>
<td>Severe limitation of physical activity: dyspnoea at rest, with increased symptoms with any level of physical activity (symptomatically severe heart failure).</td>
<td>16</td>
</tr>
</tbody>
</table>
Aetiology of Heart Failure

95%

Hypertensive heart disease

Valvular heart disease

Dilated CMP (idiopathic, viral, alcohol, chemotherapy)

Rare causes:
- postpartum
- tachy-cardiomyopathy
- infiltrative - haemochromatosis, amyloidosis, sarcoidosis
- muscle disorders (myotonic dystrophy, muscular dystrophy)
- infective (HIV)
- inherited disorders
- endocrine (phaeo, hyperthyroid, acromegaly)
Compensatory Mechanisms

- Body “sensing” poor perfusion as hypovolaemia
- Mechanisms evolved to save our ancestors

<table>
<thead>
<tr>
<th>Response</th>
<th>Short term Effects</th>
<th>Long term Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salt and water retention</td>
<td>Augments preload</td>
<td>Pulmonary congestion/ oedema in proximal bed</td>
</tr>
<tr>
<td>Vasoconstriction</td>
<td>Maintains BP for perfusion of vital organs</td>
<td>Exacerbates pump dysfunction (inc. afterload) increases cardiac energy expenditure</td>
</tr>
<tr>
<td>Sympathetic Stimulation</td>
<td>Increases HR and ejection fraction</td>
<td>Increases energy expenditure and risk of sudden arrhythmia and death *</td>
</tr>
<tr>
<td></td>
<td>Peripheral vasoconstriction</td>
<td></td>
</tr>
</tbody>
</table>

* MAJOR CAUSE OF POOR LONG TERM OUTCOMES
Heart Failure Vicious Cycle

Cardiac injury → Pump Failure
- Reduced CO and Stroke volume
  - ↓ Renal Perfusion
  - ↓ Tissue Perfusion

Neuro-Hormonal Activation
- RAAS
- SNS

vasoconstriction, salt and water retention, +ve ino/chronotropic

β-Blockers

Progressive pump failure & LV Remodeling

ACE-I, ARB, Aldos. antag
Heart Failure Management Timeline

**Early Years**
- Non-pharmacological era:
  - Bed rest, inactivity, fluid restriction, fluid removal, (digitalis & diuretics)

**1980’s**
- Pharmacological era:
  - Digitalis, diuretics, inotropes
  - 1986 First vasodilator HF trial (V-HeFT-1) Nitrates/hydralazine

**1990’s**
- Neurohormonal intervention:
  - ACEi, beta-blockers, aldosterone antagonists

**2000’s**
- Device era:
  - CRT, ICD’s, LVAD's

**? 2010’s**
- Cellular/Genetic era:
  - Gene therapies, cell regeneration, xenotransplantation
Modern Management of Heart Failure

Aims of therapy in heart failure:

- Improve life expectancy
- Improve quality of life

The relative importance of these varies:

- between patients
- over time
Modern Management of Heart Failure

• Multidisciplinary approach

• Lifestyle measures
  ▪ Patient education/support
  ▪ Weight control (volume status)
  ▪ Dietary modification (salt, alcohol)
  ▪ Reducing fluid intake
  ▪ Smoking cessation
  ▪ Exercise and rehabilitation
  ▪ Influenza vaccination

• Pharmacological therapy – what to use and what to avoid!

• Devices and surgery
Drug Therapy in Heart Failure

- Diuretics
- Neurohormonal antagonists
  - ACE inhibitors
  - Beta blockers
  - Aldosterone antagonists
  - Angiotensin receptor blockers
- Digoxin
- Other drugs
  - Nitrates/hydralazine
  - Amiodarone
  - Warfarin
  - Aspirin
Treatment Algorithm for the Management of CHF

New diagnosis

Start ACE inhibitor and titrate upwards

Or if ACE inhibitor not tolerated (e.g., due to severe cough) Consider angiotensin-II receptor antagonist

Add beta-blocker and titrate upwards

Add spironolactone
If patient remains moderately to severely symptomatic despite optimal drug therapy listed above

Seek specialist advice for further options

Add Diuretic
Diuretic therapy is likely to be required to control congestive symptoms and fluid retention

Add Digoxin
If a patient in sinus rhythm remains symptomatic despite therapy with a diuretic, ACE inhibitor (or angiotensin-II receptor antagonist) and beta-blocker, OR if a patient is in atrial fibrillation then use as first line therapy (see page 44)

Specialist Input

Specialist

Generalist

NICE, 2003
Digoxin

- Oldest established drug treatment for HF
- Extract of Foxglove (*Digitalis purpurea*)
- 1785 William Withering
- Narrow therapeutic window
- Arrhythmias and GI side effects common

**DIG Trial 1997** (Digoxin 250μg od.)

- No mortality benefit
- Significant reduction in hospitalisations due to worsening HF
Digoxin

- Digoxin is recommended for:
  
  i. Worsening or severe heart failure due to LV systolic dysfunction despite ACE inhibitor, beta-blocker and diuretic therapy
  
  ii. Patients with AF and any degree of heart failure

NICE, 2003
Diuretics

- 1920 Organomercurial diuretics first used
- 1958 Thiazide diuretics introduced
- Useful in the acute setting and in the overloaded patient
- Rapid relief of congestive symptoms
- Exacerbate RAA system due to diuresis and natriuresis
- No evidence for mortality benefit, no effect on disease progression
- Need to up and down titrate according to symptoms

“Diuretics should be routinely used for the relief of congestive symptoms and fluid overload in patients with heart failure”
ACE Inhibitors (1)

• First ACE inhibitor - Captopril synthesised in 1977
• Undisputable evidence of reduction in mortality in chronic HF
• Review of data from 5 RCT’s
• Compared with placebo. ACEi reduce
  ▪ Mortality (p<0.0001)
  ▪ Readmission (p<0.0001)
  ▪ Reinfarction (p<0.0001)
• Benefit occurs early (30 days)

Flather *et al.*, Lancet 2000
ACE Inhibitors (2)

- ..... in symptomatic heart failure patients:
  - CONSENSUS 1987 (First ACEi trial - Enalapril 20mg bd)
  - SOLVD 1990
  - ATLAS 1999 (High v Low dose Lisinopril)

- ....in post infarct heart failure:
  - SAVE 1991 (Captopril 50mg tds)
  - AIRE 1993 (Ramipril 5mg bd)
  - TRACE 1995 (Trandolapril 4mg od)

- ....and in asymptomatic patients with LV dysfunction:
  - SOLVD 1990 (prevention arm)
  - TRACE 1995
  - SAVE 1991
ACE inhibitors (3)

“all patients with heart failure due to LV systolic dysfunction should be considered for treatment with an ACEi”

• start with low dose
• aim for trial target dose or highest tolerated dose
• Remember, some ACEi is better than none
• Symptomatic low BP (stop other vasodilators ± diuretics)
• Monitor creatinine and electrolytes
• Rise in creatinine of 30% is probably acceptable
Aldosterone & Heart Failure

Aldosterone

Na/H₂O oedema

Myocardial & Vascular fibrosis

Myocyte necrosis & scarring → LV remodeling

Impaired ANS ↓ HRV ↓ BRS

Endothelial dysfunction (NO)

Heart Failure Progression and Cardiac Death
Aldosterone Antagonists

2 currently available:

- Spironolactone
- Eplerenone

**Spironolactone**

- RALES trial 1999 (25mg od)
- NYHA III/IV on ACEi, diuretic ± digoxin
  - 30% RRR in death
  - 35% RRR in hospitalisation

NICE Recommendations on Spironolactone

“Heart failure patients who remain moderate-severely symptomatic despite OMT should be prescribed spironolactone at a dose of 12.5 - 50mg daily”

• Symptom improvement in weeks - months
• Monitor Potassium & Creatinine
• If hyperkalaemia occurs, halve dose
• S.E. Breast discomfort +/- gynaecomastia
Aldosterone antagonist for heart failure post MI

**EPHESUS**

**AMI, LVEF ≤ 40%, Clinical HF, Standard Therapy**

- **Eplerenone**
  - 25–50 mg od
  - n = 3319

- **Placebo**
  - n = 3313

Randomise 3–14 Days Post–AMI

**Primary End Points:**
- All-cause mortality
- CV mortality/CV hospitalisation*

**Secondary End Points:**
- CV mortality
- All-cause mortality/all-cause hospitalisations
- CV hospitalisations

1012 Deaths

*CV hospitalisation = hospitalisation for heart failure, MI, stroke, or ventricular arrhythmia

Pitt B et al. Cardiovasc Drugs and Therapy 2001; 15: 79-87
All-Cause Mortality

RR = 0.85 (95% CI, 0.75-0.96)

P = 0.008

CV Mortality/Hospitalisation

Cumulative Incidence (%)

Placebo
Eplerenone

RR = 0.87 (95% CI, 0.79 - 0.95)

P = 0.002

Summary: Aldosterone antagonists

• ACE inhibitors and ARB’s do not adequately suppress aldosterone levels, leading to aldosterone ‘escape’

• When added to conventional therapy in HF aldosterone receptor antagonists are cardioprotective
  ▪ ↓ all-cause mortality
  ▪ ↓ cardiac mortality
  ▪ ↓ hospitalisations for heart failure

• These benefits are in addition to those conferred by ACE inhibitors
Aldosterone antagonists: -
- Spironolactone or Eplerenone?

- Licensed for different indications
- No evidence for beneficial effect of Spironolactone in heart failure post MI
- No evidence for beneficial effect of Eplerenone in CHF
- 10% incidence of gynaecomastia with Spironolactone
- Similar problems with hyperkalaemia
- Eplerenone significantly more expensive
Beta Blockers in Heart Failure

• β blockers protect against plasma Norepinephrine/Epinephrine
• More patients in trials with beta-blockers than ACEi

<table>
<thead>
<tr>
<th>Name</th>
<th>Drug</th>
<th>Year</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDC</td>
<td>Metoprolol tartrate 100-150mg/day</td>
<td>1993</td>
<td>383</td>
</tr>
<tr>
<td>MERIT-HF</td>
<td>Metoprolol succinate 200mg od</td>
<td>1999</td>
<td>3991</td>
</tr>
<tr>
<td>US Carvediolol HF Program</td>
<td>Carvedilol 25-50mg bd</td>
<td>1996</td>
<td>1094</td>
</tr>
<tr>
<td>CIBIS II</td>
<td>Bisoprolol 10mg 0d</td>
<td>1999</td>
<td>2647</td>
</tr>
<tr>
<td>COPERNICUS</td>
<td>Carvedilol 25-50mg bd</td>
<td>2000</td>
<td>2289</td>
</tr>
</tbody>
</table>
Beneficial effects of Beta Blockers

**MERIT-HF**

- RRR 34%

**COPERNICUS**

- RRR 35%

**CIBIS II**

- RRR 32%
and in the Elderly?

SENIORS Trial (2005)

• First HF outcome trial restricted to elderly (mean age 76 yrs)

• Nebivolol (Long acting, cardioselective, vasodilating properties)

Nebivolol initiated at 1.25mg. Target 10mg od.
Beta blockers and heart failure

“All patients with heart failure should be considered for treatment with a beta blocker”

Which beta blocker, and what dose?

• Stick to beta blocker with evidence base
• 3 licensed in UK (Carvedilol, Bisoprolol & Nebivolol)

  Bisoprolol (β1 selective).

  Carvedilol (Mixed α1, β1, β2 antag)

  Nebivolol (β1 selective & Vasodil. ? via NO)

• What dose? - “Start low, go slow”
• Aim for trial doses (or max tolerated)
• Some better than none!
Beta blockers - practical advice

• Initiate slowly, in stable patients (i.e. no congestion)

• B blocker or ACEi first?

  CIBIS III - Mild-moderate HF
  bisoprolol or enalapril first
  No difference in mortality / hospitalisation

• What if increasing congestion?

  Double diuretic, if no better halve β blocker (? stop in short term)

• What if profound fatigue/bradycardia?

  Unusual. Halve dose, reassess

• Inform patients:

  Primary aim of Rx is to prevent worsening HF & ↑ survival
  If symptoms do improve, it can take weeks - months
  Temporary deterioration of symptoms in 20 - 30%
Angiotensin Receptor Blockers

- ACEi fail to block RAS completely
- ARB’s prevent binding of angiotensin II to type 1 receptor
Angiotensin Receptor Blockers

Chronic Heart Failure Trials

- ELITE II 2000 (non-inferiority to ACEi, better tolerated)
- VALHeFT 2002 (ARB + ACEi ↓ hospitalisations, but not mortality)

Post MI heart failure trials

- OPTIMAAL 2002 (ACEi better at reducing mortality)
- VALIANT 2003 (ARB similar to ACEi at reducing mortality)
CHARM Trial

7,601 patients with heart failure

3 Individual component randomized trials with the ARB candesartan (4 or 8 mg/day, titrated to target dose of 32 mg) or placebo

- **CHARM Added**
  - Patients with LVEF <40% and treated with an ACE-inhibitor

- **CHARM Alternative**
  - Patients with LVEF <40% and ACE-inhibitor intolerant

- **CHARM Preserved**
  - Patients with LVEF >40% with or without ACE-inhibitor

**Endpoints** (follow-up minimum 2 years):
- Primary – Component trials: cardiovascular mortality or HF hospitalization
- Primary – Overall trial results: All-cause mortality
CHARM TRIAL

Alternative Trial

CV Mortality or CHF hospitalization

\[ p = 0.0004 \]

Added Trial

CV Mortality or CHF hospitalization

\[ p = 0.011 \]
Angiotensin Receptor Blockers - Summary

• ARB’s are a good alternative to ACEi in symptomatic patients intolerant to ACEi to improve morbidity and mortality

• ARB’s can be considered in combination with ACEi in patients who remain symptomatic, to reduce mortality and hospitalisation for HF (CHARM-added).

European Society of Cardiology CHF guidelines. 2005.
Heart Failure Chronic Disease Management

Follow up interval should be *maximum* of 6 months

- Functional capacity – History / NYHA class / QOL / 6MW / CPX
- Assessment of fluid status – weight / L+S BP / clinical examination
- Assessment of cardiac rhythm – clinical examination, ECG
- Laboratory assessment – minimum U+E’s
- Management plan – compliance with diet, fluid, exercise, lifestyle
- Co-medications – check all medications (prescribed and OTC)
- Medical complications – angina, depression, renal failure, anaemia
Heart Failure Specialist Nurse

- Implements treatment algorithms
- Link between primary and secondary care
- Emotional support
- Continued adjustment and optimisation of treatment
- Point of contact - early intervention to reduce admission
- Monitoring weights and blood tests
- Promoting long term compliance
- Educating patients and family - promoting self help
- Advanced HF-links with palliative care
Patient Self Monitoring

• Patients can monitor their volume status by daily weighing and adjustment of diuretic regime.

• Requires education and support

• Patients taught to recognise early signs of decompensation and how to seek professional help

• Key role for Heart Failure Specialist Nurse (education & support)
Drugs to avoid in Heart Failure

• Anti-inflammatory medication (NSAIDS, COX 2 inhibitors)
• Class 1 antiarrhythmic agents (e.g. flecainide, lignocaine)
• Calcium channel antagonists
  - Rate limiting non-dihydropyridine (verapamil, diltiazem)
  - First generation dihydropyridine (nifedipine)
• Tricyclic antidepressants
• Lithium
• St Johns Wort
• Cautious use of steroids
Depression: Common and important

• Consider depression in all patients with heart failure
• Prevalence of 30% in non-hospitalised HF patients
• Diagnosis more common in those with physical symptoms and poorer physical functioning
• Depressive symptoms strongly linked with worse outcome
• But, risk/benefit of antidepressants carefully
When to Refer to a Specialist?

- Diagnostic uncertainty
- Heart failure due to valve disease
- Heart failure due to diastolic dysfunction
- Advanced heart failure (NYHA class III and IV)
- Severely impaired LV
- Patients with significant co-morbidity
- Symptomatic arrhythmia
- Women planning pregnancy
- HF no longer manageable in home setting
Cardiac Resynchronisation Therapy
- an option in advanced heart failure

What is it?

• Cardiac Resynchronisation Therapy (CRT), or, BiV Pacing
• CRT first described in 1980’s
• Introduced clinically a decade later
• Routine pacemaker implant (local anaesthetic)
• With or without ICD capability
Achieving Cardiac Resynchronisation

Goal: Atrial synchronous biventricular pacing

Transvenous approach for left ventricular lead via coronary sinus

Back-up epicardial approach
Why do it?

- LBBB occurs in approx 30% of HF patients.
- LBBB is an independent predictor of increased mortality in HF
- Delayed LV activation (His-Purkinje system / conduction block / fibrosis)
Mechanical Dyssynchrony
Mechanical Dyssynchrony is Bad News!

- Early septal contraction → pressure low → no ejection
- Late postero-lateral contraction → paradoxical stretch (early contracting segments)
- Early / late contraction = “wasted work”
- Increased time in IVC and IVR.
- Reduced ejection / diastolic filling time
- Increased global / regional wall stress
- Increased myocardial O₂ consumption
- Protracted mitral regurgitation (LV dilatation / lateral papillary muscle)
Abnormal local wall strain in LBBB

Longer

Relax

Shorter

Normal

LBBB
What are the benefits of CRT?

Cumulative Enrollment in CRT Randomised Trials

Study Results
Proven Benefits of CRT

Improves patient’s functional status
• ↑ 6 min walk distance by ~ 20%
• ↓ NYHA class by 0.5-0.8 points (58% v 37% ↓ by at least 1 class)
• ↑ VO2 Max: by 10-15%
• QOL (MLWHF) - Significantly improved (8.4 points)

Improves “pump” function
• 26% ↓ in LVESV at 18 months
• Significant reduction in MR regurgitant area
• Approx 6% ↑ in EF

Reduces Hospitalisation
• ↓ relative risk of admission for worsening CCF by 52%

Reduces cardiovascular mortality
• Relative risk reduction of 40% in all cause mortality
Response to CRT

Pre CRT

Post CRT
What’s the catch?

- Procedural risk (PTX, infection, lead displacement)
- 5% failure to deploy LV lead
- Of those successfully implanted - 30% of patients do not respond.

  i. Viable myocardium (cannot pace scar tissue)
  ii. Shot ventricular function (RV / LV)
  iii. QRS is imperfect marker for mechanical dyssynchrony
  iv. LV lead position
Who benefits from CRT?

- NYHA Class III or ambulatory Class IV
- LVEF ≤ 35%
- Sinus rhythm
- Optimal medical therapy
- Evidence of
  - QRS ≥ 150 msec
  - or, 120-149 msec with Echo evidence